Exosomes increased angiogenesis in papillary thyroid cancer microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Tumour-derived exosomes mediate intercellular communication within the tumour microenvironment (TME).
• Hypoxia is a common feature of solid tumours, influencing cancer cell behaviour and exosome content.
• Exosomes play a role in angiogenesis, a critical process for tumour growth and metastasis.

Purpose of the Study:

• To investigate the role of tumour-derived exosomes from hypoxic papillary thyroid cancer cells in angiogenesis.
• To identify specific miRNAs within these exosomes that regulate endothelial cell function.
• To elucidate the molecular mechanisms by which these exosomes promote angiogenesis.

Main Methods:

• Isolation and characterization of exosomes from papillary thyroid cancer cell lines (BCPAP, KTC-1) under normoxic and hypoxic conditions.
• Assessment of exosome-mediated angiogenesis using human umbilical vein endothelial cells (HUVECs) in vitro and in vivo.
• miRNA profiling of exosomes and functional studies involving miRNA mimics and inhibitors (e.g., miR-21-5p knockdown).
• Target gene validation (TGFBI, COL4A1) using luciferase assays and Western blotting.

Main Results:

• Exosomes from hypoxic papillary thyroid cancer cells significantly enhanced HUVEC angiogenesis compared to normoxic controls.
• miR-21-5p was upregulated in exosomes from hypoxic BCPAP cells and its knockdown attenuated the pro-angiogenic effect.
• miR-21-5p directly targeted and suppressed TGFBI and COL4A1, leading to increased endothelial tube formation.
• Elevated exosomal miR-21-5p levels were detected in the sera of papillary thyroid cancer patients.

Conclusions:

• Hypoxic papillary thyroid cancer cells secrete exosomes enriched with miR-21-5p, which promotes angiogenesis.
• The exosomal miR-21-5p/TGFBI and miR-21-5p/COL4A1 pathways represent a novel mechanism for tumour-induced angiogenesis.
• Exosomal miR-21-5p in patient sera may serve as a potential biomarker for papillary thyroid cancer.